|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Impact of chronic disease self-management programs on type 2 diabetes management in primary care显示文摘AIM: To assess the effectiveness of the Chronic Disease Self-Management Program(CDSMP) on glycated hemoglobin A1c(HbA1c) and selected self-reported measures.METHODS: We compared patients who received a diabetes self-care behavioral intervention, the CDSMP developed at the Stanford University, with controls whoreceived usual care on their HbA1c and selected self-reported measures, including diabetes self-care activities, health-related quality of life(HRQOL), pain and fatigue. The subjects were a subset of participants enrolled in a randomized controlled trial that took place at seven regional clinics of a university-affiliated integrated healthcare system of a multi-specialty group practice between January 2009 and June 2011. The primary outcome was change in HbA1c from randomization to 12 mo. Data were analyzed using multilevel statistical models and linear mixed models to provide unbiased estimates of intervention effects.RESULTS: Demographic and baseline clinical characteristics were generally comparable between the two groups. The average baseline HbA1c values in the CDSMP and control groups were 9.4% and 9.2%, respectively. Significant reductions in HbA1c were seen at 12 mo for the two groups, with adjusted changes around 0.6%(P < 0.0001), but the reductions did not differ significantly between the two groups(P = 0.885). Few significant differences were observed in participants' diabetes self-care activities. No significant differences were observed in the participants' HRQOL, pain, or fatigue measures.CONCLUSION: The CDSMP intervention may not lower HbA1c any better than good routine care in an integrated healthcare system. More research is needed to understand the benefits of self-management programs in primary care in different settings and populations. | Samuel N Forjuoh Marcia G Ory Luohua Jiang Ann M Vuong Jane N Bolin | 2014 | World Journal of Diabetes2014，5，3： | 6 |
| 2 | Therapeutic and prophylactic thalidomide in TNBS-induced colitis: Synergistic effects on TNF-α, IL-12 and VEGF production显示文摘AIM: To evaluated the therapeutic and prophylactic effect of thalidomide on 2, 4, 6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Thalidomide has been reported to downregulate the expression of tumor necrosis factor a (TNF-α), IL-12, and vascular endothelial growth factor (VEGF), hallmarks of intestinal inflammation in Crohn's disease (CD). METHODS: Male Wistar rats were divided in five groups of ten animals each. Four groups received a rectal infusion of TNBS in ethanol. The first group was sacrificed 7 d after colitis induction. The second and third groups received either thalidomide or placebo by gavage and were sacrificed at 14 d. The fourth group received thalidomide 6 h before TNBS administration, and was sacrificed 7 d after induction. The fifth group acted as the control group and colitis was not induced. Histological inflammatory scores of the colon were performed and lamina propria CD4+ T cells, macrophages, and VEGF+ cells were detected by immunohistochemistry. TNF-a and IL-12 were quantified in the supernatant of organ cultures by ELISA. RESULTS: Significant reduction in the inflammatory score and in the percentage of VEGF+ cells was observed in the group treated with thalidomide compared with animals not treated with thalidomide. Both TNF-αand IL-12 levels were significantly reduced among TNBS induced colitis animals treated with thalidomide compared with animals that did not receive thalidomide. TNF-αlevels were also significantly reduced among the animals receiving thalidomide prophylaxis compared with untreated animals with TNBS-induced colitis. Intestinal levels of TNF-αand IL-12 were significantly correlated with the inflammatory score and the number of VEGF+ cells. CONCLUSION: Thalidomide significantly attenuates TNBS-induced colitis by inhibiting the intestinal production of TNF-α, IL-12, and VEGF. This effect may support the use of thalidomide as an alternate approach in selected patients with CD. | Ana Teresa Carvalho Heitor Souza Antonio Jose Carneiro Morgana Castelo-Branco Kalil Madi Alberto Schanaider Flavia Silva Fernando Antonio Pereira Júnior Márcia G Pereira Cláudio Tortori Ilana Dines Jane Carvalho Eduardo Rocha Celeste Elia | 2007 | World Journal of Gastroenterology2007，13，15： | 6 |
| 3 | Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial显示文摘 | Kris V Kowdley Eric Lawitz Israel Crespo Tarek Hassanein Mitchell N Davis Michael DeMicco David E Bernstein Nezam Afdhal John M Vierling Stuart C Gordon Jane K Anderson Robert H Hyland Hadas Dvory-Sobol Di An Robert G Hindes Efsevia Albanis William T Symo | 2013 | The Lancet2013，，9883： | 3 |
| 4 | 澳大利亚初级保健诊所新发腰背痛患者的预后:起始队列研究显示文摘目的估计初级保健诊所内新发腰背痛患者的1年预后,并确定其预后因素。设计1年随访队列研究。地点澳大利亚悉尼的初级保健诊所。参试者初级保健诊所接诊的973例非特异性腰背痛连续患者(平均年龄43.3岁,男性54.8%)。该起始队列患者腰背痛时间不足两周,征集自170名全科医生、理疗师或按摩师诊所。主要评估指标参试者完成基线调查问卷后,分别于初次就诊后6周、3个月和21个月时复查评估。评估内容包括:工作恢复情况、功能恢复情况和疼痛消失情况。潜在预后因素与恢复所需时间的关联性用Cox回归建模分析。结果12个月随访率〉97%。基线时工作能力下降的患者半数在14天内恢复了以前的工作状态(95%可信区间11-17天),83%在3个月内恢复。残疾(中位恢复时间31天,25-37天)和疼痛(中位58天,52-63天)则需要较长的时间才能恢复。只有72%的受试者于基线访问后12个月获得完全康复。高龄、赔偿诉讼、疼痛较重、就诊前腰背痛时间较长、就诊前因疼痛活动减少天数较多、抑郁情绪以及预期危险持续与所需恢复时问较长相关。结论在这个急性腰背痛初级保健患者队列,患者的预后并不像临床指南声称的那样乐观。多数患者的恢复缓慢。近三分之一的患者在腰背痛发作后1年尚未恢复。 | Nicholas Henschke Christopher G Maher Kathryn M Refshauge Robert D Herbert Robert G Cumming Jane Bleasel John York Anurina Das James H McAuley 蓝恭涛(译) | 2008 | 英国医学杂志中文版2008，11，6： | 2 |
| 5 | Immunisation of Channel Catfish, Ictalurus punctatus, with Ichthyophthirius multifiliis Immobilisation antigens elicits serotype-specific protection 显示文摘 | Wang Xu-Ting Clark T G Jane Noe | 2002 | Fish Shellfish Immunol2002，13，： | 2 |
| 6 | Regulatory challenges for new drugs to treat obesity and eomorbid metabolic disorders 显示文摘 | David J H Jane G Sharon L S | 2009 | Br J ClinPharmaeol2009，68，6： | 1 |
| 7 | Characterization of SU1 isoamylase,a determinant of storage starch structure in maize显示文摘 | Wong K S Jane J L Myers A M James M G | 1998 | Plant physiology1998，117，： | 1 |
| 8 | Multiple-ion-doped lithium nickel oxides as cathod materials for lithium-ion batteries显示文摘 | Wang G X Steve B Jane Y | 2003 | Journal of Power Sources2003，，： | 1 |
| 9 | A model of family-centered care and satisfaction predictors:the critical care family assistance program显示文摘 | Jane D Jeffery V Sue G | 2005 | Chest2005，128，3： | 1 |
| 10 | Regulatory role of SGTI in early R Gene-Mediated plant defenses显示文摘 | Mark J Paul M Katherine K Bart J Jonathan D G Jane E | 2002 | Science2002，295，15： | 1 |
| 11 | Exposure and Markups显示文摘 | Allayannis G and Jane Ihrig | | Review of Financial Studies 140，2001，： | 1 |
| 12 | Convergence of normal stem cell and cancer stem cell developmental stage:Implication for differential therapies显示文摘Increased evidence shows that normal stem cells may contribute to cancer development and progression by acting as cancer-initiating cells through their interactions with abnormal environmental elements.We postulate that normal stem cells and cancer stem cells (CSC) possess similar mechanisms of self-renewal and differentiation.CSC can be the key to the elaboration of anti-cancer-based therapy.In this article,we focus on a controversial new theme relating to CSC.Tumorigenesis may have a critical stage characterized as a 'therapeutic window',which can be identified by asso-ciation of molecular,biochemical and biological events.Identifying such a stage can allow the production of more effective therapies (e.g.manipulated stem cells) to treat several cancers.More importantly,confirming the existence of a similar therapeutic window during the conversion of normal stem cells to malignant CSC may lead to targeted therapy specifically against CSC.This conversion information may be derived from investigating the biological behaviour of both normal stem cells and cancerous stem cells.Currently,there is little knowledge about the cellular and molecular mechanisms that govern the initiation and maintenance of CSC.Studies on co-evolution and interdependence of cancer with normal tissues may lead to a useful treatment paradigm of cancer.The crosstalk between normal stem cells and cancer formation may converge developmental stages of different types of stem cells (e.g.normal stem cells,CSC and embryonic stem cells).The differential studies of the convergence may result in novel therapies for treating cancers. | Shengwen Calvin Li Katherine L Lee Jane Luo Jiang F Zhong William G Loudon | 2011 | World Journal of Stem Cells2011，3，9： | 1 |
| 13 | A tabletop exercise to assess a hospital emergency blood management contingency plan in a simulated acute blood shortage显示文摘 | Galloway M J Jane G Sudlow L Trattles J Watson J | 2008 | Transfusion Medicine2008，18，5： | 1 |
| 14 | Pituitary tumors 显示文摘 | Mehta G Jane JJ | 2012 | Curt Opin Neurol2012，25，： | 1 |
| 15 | Changes in structure and properties of starch of four botanical sources dispersed in the ionic liquid,1-butyl-3-methylimidazolium chloride 显示文摘 | David G Stevenson Atanu Biswas Jay-lin Jane | 2007 | Carbohydrate Polymers2007，67，： | 1 |
| 16 | Electrochemical properties of nanosize Sn-coated graphite anodes in lithiumion cells显示文摘 | Wang G X Jane Yao Jung-Ho Ahn | 2004 | J Appl Electrochem2004，34，2： | 1 |
| 17 | Magnetic resonance spectroscopy reveals that activated rnonoeytes contribute to neuronal injury in SIV neuroAIDS显示文摘 | Kenneth W Susan W Jane G | 2005 | Clin Invest2005，115，9： | 1 |
| 18 | Pituitary surgery:transsphenoidal approach 显示文摘 | Jane JA Thapar K Kaptain G J | 2002 | Neurosurgery2002，51，2： | 1 |
| 19 | Task Force 1: the changing profile of congenital heart disease in adult life显示文摘 | Carole A Warnes Richard Liberthson Gordon K Danielson Annie Dore Louise Harris Julien I.E Hoffman Jane Somerville Roberta G Williams Gary D Webb | 2001 | Journal of the American College of Cardiology2001，，5： | 1 |
| 20 | Density, heat capacity and thermal conductivity of liquid egg products 显示文摘 | Jane s R Coimbra Ana L G Luis A M | 2006 | Joumal of Food Engineering2006，74，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员